OLMA Olema Pharmaceuticals
- 10.600
- +0.430+4.23%
Olema Pharmaceuticals News
OPEN, BCRX and AWIN Among Pre-market Gainers
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Olema Oncology Announces Promising New Data for Palazestrant in Combination With Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $25 to $28.
Olema Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 172.9% HC Wainwright & Co. $25 → $28 Maintains Buy 04/02/2024 133.92% Goldman Sachs → $24 Initi
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position
Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration
Olema Pharmaceuticals Q1 EPS $(0.56) Misses $(0.51) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 20 percent increase over losses of $
Olema Pharmaceuticals | 10-Q: Quarterly report
Olema Pharmaceuticals Cash, Cash Equivalents and Marketable Securities as of March 31 Were $249M >OLMA
Olema Pharmaceuticals Cash, Cash Equivalents and Marketable Securities as of March 31 Were $249M >OLMA
Olema Pharmaceuticals 1Q Loss/Shr 56c >OLMA
Olema Pharmaceuticals 1Q Loss/Shr 56c >OLMA
Press Release: Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination wit
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, G
Olema Oncology Announces New Clinical Data for Palazestrant in Combination With Ribociclib to Be Presented at the 2024 ESMO Breast Cancer Annual Congress
Olema Oncology Announces New Clinical Data for Palazestrant in Combination With Ribociclib to Be...
Analysis
Price Target
No Data
